Ocio, E. M., Perrot, A., Bories, P., San-Miguel, J. F., Blau, I. W., Karlin, L., . . . Moreau, P. (2023). Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Citación estilo ChicagoOcio, Enrique M., et al. Efficacy and Safety of Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Ineligible/with No Immediate Intent for Autologous Stem Cell Transplantation. 2023.
Cita MLAOcio, Enrique M., et al. Efficacy and Safety of Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Ineligible/with No Immediate Intent for Autologous Stem Cell Transplantation. 2023.